Compare Stocks

→ Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
IKT Inhibikase Therapeutics	$1.36 -2.9%	$2.00	$0.79 ▼ $4.35	$8.81M	1.31	118,061 shs	34,612 shs
PALI Palisade Bio	$6.94 -1.7%	$5.90	$3.82 ▼ $36.60	$5.90M	1.25	899,112 shs	34,420 shs
TTNP Titan Pharmaceuticals	$6.82	$7.18	$5.00 ▼ $16.60	$6.23M	1.32	10,752 shs	343 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-26.88%
IKT Inhibikase Therapeutics	-2.86%	+1.49%	-36.15%	-49.25%	-62.82%
PALI Palisade Bio	-1.70%	-4.80%	+28.04%	+5.15%	-70.90%
TTNP Titan Pharmaceuticals	0.00%	+1.79%	-5.28%	-3.26%	-56.28%

Elon’s New Device is About to Shock the World (Ad)

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.4725 of 5 stars	3.5	0.0	0.0	0.0	0.0	1.7	1.3
PALI Palisade Bio	1.3478 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.6
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	3.00	Buy	$27.00	1,885.29% Upside
PALI Palisade Bio	3.00	Buy	$131.25	1,791.21% Upside
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TTNP, IKT, BVXV, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/1/2024	PALI Palisade Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.50
4/16/2024	PALI Palisade Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.50
3/5/2024	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
IKT Inhibikase Therapeutics	$260K	33.90	N/A	N/A	$1.78 per share	0.76
PALI Palisade Bio	$250K	23.60	N/A	N/A	$18.29 per share	0.38
TTNP Titan Pharmaceuticals	$1K	6,233.48	N/A	N/A	$8.82 per share	0.77

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$3.56	N/A	N/A	N/A	-5,886.15%	-107.54%	-91.82%	5/20/2024 (Estimated)
PALI Palisade Bio	-$12.30M	-$27.14	N/A	∞	N/A	N/A	-89.68%	-76.18%	5/10/2024 (Estimated)
TTNP Titan Pharmaceuticals	-$5.57M	-$8.20	N/A	∞	N/A	-2,014.71%	-165.90%	-105.75%	5/20/2024 (Estimated)

Latest TTNP, IKT, BVXV, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	IKT Inhibikase Therapeutics	-$0.78	-$0.63	+$0.15	-$0.63	N/A	N/A
3/26/2024	Q4 2023	PALI Palisade Bio	N/A	-$3.75	-$3.75	-$3.75	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
IKT Inhibikase Therapeutics	N/A	4.13	4.13
PALI Palisade Bio	N/A	5.15	5.15
TTNP Titan Pharmaceuticals	N/A	5.55	5.55

Ownership

Institutional Ownership

Company	Institutional Ownership
BVXV BiondVax Pharmaceuticals	11.83%
IKT Inhibikase Therapeutics	3.81%
PALI Palisade Bio	11.79%
TTNP Titan Pharmaceuticals	31.49%

Insider Ownership

Company	Insider Ownership
BVXV BiondVax Pharmaceuticals	6.03%
IKT Inhibikase Therapeutics	20.30%
PALI Palisade Bio	2.24%
TTNP Titan Pharmaceuticals	24.93%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
IKT Inhibikase Therapeutics	8	6.48 million	5.16 million	Not Optionable
PALI Palisade Bio	9	850,000	833,000	Not Optionable
TTNP Titan Pharmaceuticals	4	914,000	686,000	Optionable

TTNP, IKT, BVXV, and PALI Headlines

Source	Headline
	Titan Pharmaceuticals (NASDAQ:TTNP) Shares Cross Below Two Hundred Day Moving Average of $7.02 americanbankingnews.com - May 9 at 5:54 AM
	Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com americanbankingnews.com - May 9 at 3:44 AM
	India's Titan misses Q4 profit view as surging gold prices dampen demand reuters.com - May 3 at 9:50 AM
	StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP) americanbankingnews.com - May 1 at 2:14 AM
	New Release: The Less Expensive Secretlab Titan Evo Lite Is Nearly as Good as the Titan Evo ign.com - April 21 at 8:14 AM
	2005 Nissan Titan autoblog.com - March 25 at 4:09 AM
	Titan Pharmaceuticals Inc (TTNP) uk.investing.com - March 2 at 9:17 AM
	Titan Pharmaceuticals, Inc. (TN70.F) au.finance.yahoo.com - February 20 at 2:08 PM
	Titan Pharmaceuticals Inc TTNP morningstar.com - February 3 at 2:27 PM
	Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria finanznachrichten.de - January 26 at 9:07 PM
	Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria finance.yahoo.com - January 25 at 7:32 PM
	Titan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Dates benzinga.com - January 10 at 1:05 PM
	Titan Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits cbonds.com - December 30 at 10:29 AM
	Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratio finanznachrichten.de - December 29 at 8:01 AM
	Barbie, the Titan submersible and everything else we Googled in 2023 washingtonpost.com - December 28 at 8:29 PM
	Titan Pharmaceuticals Announces Reverse Stock Split and Ratio finance.yahoo.com - December 28 at 8:29 PM
	Untitled Attack on Titan Codes (December 2023) twinfinite.net - December 27 at 3:54 PM
	2023 Nissan Titan XD Review autoblog.com - December 27 at 3:54 PM
	Attack on Titan Revolution Codes (December 2023) twinfinite.net - December 20 at 10:44 PM
	Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors finance.yahoo.com - October 16 at 8:58 PM
	More presumed human remains recovered from imploded Titan submersible today.com - October 14 at 10:10 AM
	Titan Pharmaceuticals reports $9.5M private placement of convertible preferred stock seekingalpha.com - September 18 at 11:34 AM
	Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock finance.yahoo.com - September 18 at 11:34 AM
	Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide finance.yahoo.com - August 28 at 5:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Inhibikase Therapeutics

NYSE:IKT

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Palisade Bio

NASDAQ:PALI

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Titan Pharmaceuticals

NASDAQ:TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial